Articles

Browse normalized, publication-ready research with direct links to its evidence and source.

Loading articles data…

Anonymous aggregate analytics use the connection IP transiently only to derive country; the IP is not stored in analytics data. DNT and GPC are honored, with 90-day retention. IP Geolocation by DB-IP.

CANNABISHUB:EUMedical cannabis research platform

conditions cannabinoids studies medicines library about

Readable research linked to original sources

Articles

Browse normalized, publication-ready research with direct links to its evidence and source.

Filters

Clear all

Article type

Publication year

19172026

From yearTo year

Keyword

Active filter

Author: Peggy Compton

1 articles

Newest first

Research Article 2026CC BYCC BY allows this article to remain publicly readable here. Any reuse must still follow the recorded source terms.Free full text

An opioid-withholding human laboratory paradigm during opioid agonist treatment for opioid use disorder and chronic pain: Phase- and dose-dependent effects of cannabidiol.

Gabriel P. A. Costa, Mehmet Sofuoglu, Peggy Compton, Mohini Ranganathan, Brian Pittman, Joao P. De Aquino

Even during opioid agonist treatment (OAT) for opioid use disorder (OUD), chronic pain remains common and unrelieved, as opioids impair endogenous pain modulation. Cannabidiol (CBD) may represent a non-opioid adjunct, but its effects among persons with co-occurring OUD and chronic pain receiving OAT are unknown. We conducted a randomized, double-blind, placebo-controlled crossover study evaluating acute oral CBD (…

Drug discovery Neuroscience

Neuropsychopharmacology PubMed Central Open Access↗

Open article record in new tab ↗

End of results

The service organizes published evidence. It does not provide medical advice.